** Shares of drug developer Cogent Biosciences COGT.O rise 19.4% to $9.05 premarket
** Co says its drug, bezuclastinib, showed a statistically significant reduction in symptoms in patients with mastocytosis, a type of blood disorder
** Mastocytosis is a disease where the body makes too many of a type of white blood cell called mast cells, which build up in places like the bone marrow, skin or organs
** COGT expects to file a marketing application for the treatment by the end of 2025
** Up to last close, stock down 2.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.